Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 1
1967 2
1968 2
1969 2
1970 2
1971 2
1972 5
1973 17
1974 12
1975 19
1976 15
1977 13
1978 13
1979 11
1980 10
1981 11
1982 24
1983 23
1984 31
1985 25
1986 19
1987 24
1988 17
1989 50
1990 41
1991 49
1992 41
1993 50
1994 51
1995 70
1996 53
1997 53
1998 58
1999 66
2000 72
2001 88
2002 84
2003 71
2004 65
2005 72
2006 74
2007 73
2008 72
2009 65
2010 73
2011 79
2012 88
2013 82
2014 89
2015 103
2016 85
2017 81
2018 76
2019 98
2020 89
2021 96
2022 86
2023 76
2024 25

Text availability

Article attribute

Article type

Publication date

Search Results

2,583 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Recurrent Lymphocyte-Depleted Classic Hodgkin Lymphoma"
Page 1
Hodgkin lymphoma.
Connors JM, Cozen W, Steidl C, Carbone A, Hoppe RT, Flechtner HH, Bartlett NL. Connors JM, et al. Nat Rev Dis Primers. 2020 Jul 23;6(1):61. doi: 10.1038/s41572-020-0189-6. Nat Rev Dis Primers. 2020. PMID: 32703953 Review.
Hodgkin lymphoma (HL) is a B cell lymphoma characterized by few malignant cells and numerous immune effector cells in the tumour microenvironment. ...Diagnosis is based on histological and immunohistochemical analyses of tissue from a lymph node biopsy; the t …
Hodgkin lymphoma (HL) is a B cell lymphoma characterized by few malignant cells and numerous immune effector cells in t …
How I treat nodular lymphocyte-predominant Hodgkin lymphoma.
Eichenauer DA, Engert A. Eichenauer DA, et al. Blood. 2020 Dec 24;136(26):2987-2993. doi: 10.1182/blood.2019004044. Blood. 2020. PMID: 32877522 Free article. Review.
Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare lymphoma entity with distinct pathologic and clinical characteristics. Unlike the malignant cells in classical Hodgkin lymphoma, the disease-defining lymphocyte …
Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare lymphoma entity with distinct pathologic and c …
Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results.
Advani RH, Moskowitz AJ, Bartlett NL, Vose JM, Ramchandren R, Feldman TA, LaCasce AS, Christian BA, Ansell SM, Moskowitz CH, Brown L, Zhang C, Taft D, Ansari S, Sacchi M, Ho L, Herrera AF. Advani RH, et al. Blood. 2021 Aug 12;138(6):427-438. doi: 10.1182/blood.2020009178. Blood. 2021. PMID: 33827139 Free article. Clinical Trial.
This phase 1-2 study evaluated brentuximab vedotin (BV) combined with nivolumab (Nivo) as first salvage therapy in patients with relapsed/refractory (r/r) classical Hodgkin lymphoma (cHL). In parts 1 and 2, patients received staggered dosing of BV and Nivo in cycle …
This phase 1-2 study evaluated brentuximab vedotin (BV) combined with nivolumab (Nivo) as first salvage therapy in patients with relapsed/re …
Hodgkin lymphoma.
Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Bello CM, Bierman PJ, Blum KA, Dabaja B, Duron Y, Forero A, Gordon LI, Hernandez-Ilizaliturri FJ, Hochberg EP, Maloney DG, Mansur D, Mauch PM, Metzger M, Moore JO, Morgan D, Moskowitz CH, Poppe M, Pro B, Weiss L, Winter JN, Yahalom J; NCCN Hodgkin Lymphoma. Hoppe RT, et al. J Natl Compr Canc Netw. 2011 Sep 1;9(9):1020-58. doi: 10.6004/jnccn.2011.0086. J Natl Compr Canc Netw. 2011. PMID: 21917626 No abstract available.
Hodgkin's lymphoma in adults.
Townsend W, Linch D. Townsend W, et al. Lancet. 2012 Sep 1;380(9844):836-47. doi: 10.1016/S0140-6736(12)60035-X. Epub 2012 Jul 25. Lancet. 2012. PMID: 22835602 Free article. Review.
Management of Hodgkin's lymphoma continues to develop. Outcomes for patients with favourable-risk, early-stage disease are excellent, and serial reductions in intensity of treatment have been made to retain the excellent prognosis while reducing the la …
Management of Hodgkin's lymphoma continues to develop. Outcomes for patients with favourable-risk, early-stage disease …
Hodgkin lymphoma: 2016 update on diagnosis, risk-stratification, and management.
Ansell SM. Ansell SM. Am J Hematol. 2016 Jun;91(4):434-42. doi: 10.1002/ajh.24272. Am J Hematol. 2016. PMID: 27001163 Free article. Review.
DISEASE OVERVIEW: Hodgkin lymphoma (HL) is an uncommon B-cell lymphoid malignancy affecting 9,050 new patients annually and representing approximately 11.2% of all lymphomas in the United States. ...Patients with early stage disease are typically treat …
DISEASE OVERVIEW: Hodgkin lymphoma (HL) is an uncommon B-cell lymphoid malignancy affecting 9,050 new patients annually …
Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse.
Moskowitz CH, Walewski J, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH, Chen AI, Stiff P, Viviani S, Bachanova V, Sureda A, McClendon T, Lee C, Lisano J, Sweetenham J. Moskowitz CH, et al. Blood. 2018 Dec 20;132(25):2639-2642. doi: 10.1182/blood-2018-07-861641. Epub 2018 Sep 28. Blood. 2018. PMID: 30266774 Free article. Clinical Trial.
The phase 3 AETHERA trial established brentuximab vedotin (BV) as a consolidative treatment option for adult patients with classical Hodgkin lymphoma (cHL) at high risk of relapse or progression after autologous hematopoietic stem-cell transplantation (auto-HSCT). . …
The phase 3 AETHERA trial established brentuximab vedotin (BV) as a consolidative treatment option for adult patients with classical Hodg …
Nodular lymphocyte predominant Hodgkin lymphoma: Experience of Polish Pediatric Leukemia/Lymphoma Study Group.
Klekawka T, Balwierz W, Brozyna A, Chaber R, Dadela-Urbanek A, Koltan A, Kwasnicka J, Mitura-Lesiuk M, Muszynska-Roslan K, Przybyszewski B, Ruranska I, Smalisz K, Mizia-Malarz A, Stachowicz-Stencel T, Stolarska M, Wziatek A, Zielezinska K, Skoczen S. Klekawka T, et al. Pediatr Hematol Oncol. 2021 Oct;38(7):609-619. doi: 10.1080/08880018.2021.1894278. Epub 2021 Mar 18. Pediatr Hematol Oncol. 2021. PMID: 33734010
Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL) is a rare clinical entity. To investigate NLPHL clinical course and treatment a survey was performed within Polish Pediatric Leukaemia/Lymphoma Study Group (PPLLSG) participating centers. . …
Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL) is a rare clinical entity. To investigate NLPHL clinical cou …
Treatment of relapsed and refractory Hodgkin Lymphoma.
von Tresckow B, Moskowitz CH. von Tresckow B, et al. Semin Hematol. 2016 Jul;53(3):180-5. doi: 10.1053/j.seminhematol.2016.05.010. Epub 2016 May 12. Semin Hematol. 2016. PMID: 27496309 Free PMC article. Review.
Despite the high first-line cure rates in patients with Hodgkin Lymphoma (HL) still 10%-20% of patients suffer from relapsed or refractory disease. ...For patients with recurrence after HDCT and ASCT, treatment is palliative in most cases. ...
Despite the high first-line cure rates in patients with Hodgkin Lymphoma (HL) still 10%-20% of patients suffer from relapsed o …
Lymphocyte predominant Hodgkin's disease.
Ekstrand BC, Horning SJ. Ekstrand BC, et al. Curr Oncol Rep. 2002 Sep;4(5):424-33. doi: 10.1007/s11912-002-0037-8. Curr Oncol Rep. 2002. PMID: 12162918 Review.
Lymphocyte predominant Hodgkin's disease (LPHD) is a rare type of B-cell lymphoma with unique pathologic and clinical features that distinguish it from other types of Hodgkin's disease. ...The immunophenotype of the malignant lymphocytic …
Lymphocyte predominant Hodgkin's disease (LPHD) is a rare type of B-cell lymphoma with unique pathologic and cli …
2,583 results